期刊
CURRENT OPINION IN ONCOLOGY
卷 23, 期 6, 页码 547-558出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCO.0b013e32834bd4c9
关键词
breast cancer; human epidermal growth factor 2 (HER2); neoadjuvant
类别
资金
- Fonds JC Heuson
- Breast Cancer Research Foundation
- European Society of Medical Oncology
- National Health and Medical Council of Australia (NHMRC)
- Breast Cancer Research Foundation (USA)
- MEDIC Foundation
- Fonds National de Recherche Scientifique
Purpose of review There have been recent new developments in the treatment of breast cancer that over-expresses HER2 (ERRB2/HER2 positive) and the mechanistic understanding of trastuzumab response. We review these findings and reflect on how they may influence the next generation of clinical trials in this breast cancer subtype. Recent findings Two recent trials in the neoadjuvant setting report that treatment with dual anti-HER2 agents was superior, in terms of rates of pathological complete response, to trastuzumab alone. Recent data also highlight that HER2 positive disease is biologically different according to estrogen receptor status and for long lasting clinical remissions, anti-HER2 therapy also seems to require an effective adaptive immune response. Summary We are currently in a very exciting era for therapeutic approaches in HER2 positive disease. Recent data suggest that intensive chemotherapy regimens may not be required for some women if we can determine the most potent combinations of signal inhibitors. We also propose that different clinical trials may need to be designed for HER2 positive breast cancer according to estrogen receptor status and consider incorporating immunotherapeutic approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据